Free-text search
Articles per year:
Content Types
-
Eli Lilly drops Alzheimer’s drug candidate after phase II trial
Eli Lilly is discontinuing development of its Alzheimer’s drug candidate mevidalen. The decision follows a phase II trial that failed to meet the company’s expectations – even as the pharmaceutical giant invests billions to strengthen its neurology portfolio.
-
AstraZeneca unveils major cost-cutting drive
AstraZeneca beat market expectations in the third quarter. At the same time, the company announced a cost-cutting programme expected to generate annual savings of 1.5 billion dollars.
-
Sobi proposes Börje Ekholm as new chair
Börje Ekholm, the former CEO of Ericsson, has been proposed as the new chair of Sobi.
-
SynAct Pharma signs first dengue drug deal
SynAct Pharma has entered into its first commercial partnership for resomelagon as a potential treatment for dengue fever.
-
Lilly’s triple-G drug outperforms Ozempic in head-to-head trial
Eli Lilly’s investigational drug retatrutide delivered more than twice the weight loss of rival Novo Nordisk’s Ozempic in a head-to-head phase 3 trial.
-
Ferring to buy IVF biotech in billion-dollar deal
Ferring has signed an agreement to acquire US biotechnology company Gameto in a deal worth up to $1.4 billion.
-
Danish drug candidate shows great response to two cancer types
Genmab’s hopes for petosemtamab have been boosted by positive phase II results in two cancer indications. The bispecific antibody showed promising efficacy in combination with established treatments for colorectal and head and neck cancers.
-
Abbott sharpens cancer test – detects smaller traces of tumour DNA
A single tumour DNA molecule among more than a million others. That is how small a trace of cancer Abbott’s upgraded Oncodetect test is designed to detect in the blood. The technology has now also demonstrated improved performance in clinical studies.
-
Cell therapy scrapped after patient deaths in trial — 94 per cent of staff laid off
US biotech company Artiva Biotherapeutics is discontinuing the development of a cell therapy for autoimmune diseases and laying off 94 per cent of its workforce after two patients died during a clinical trial and the treatment’s effects proved less durable than expected.
-
Björn Ursing: “What happens when trust in science erodes?”
Medical breakthroughs have transformed healthcare, but scientific progress alone is not enough. As misinformation spreads and trust in science comes under pressure, how can we ensure that healthcare decisions remain grounded in evidence? Björn Ursing explores the question in this column.
-
AstraZeneca considers move into cancer vaccines
AstraZeneca is considering developing cancer vaccines based on mRNA technology, CEO Pascal Soriot said at a conference on Tuesday, Bloomberg News reports.
-
AlzeCure CEO steps down – co-founder takes over
Two multibillion-dollar deals, the company’s first profit and an oversubscribed share issue. After an eventful year, AlzeCure Pharma is changing CEO. Martin Jönsson is stepping down after almost seven years and will be temporarily replaced by Chief Scientific Officer and co-founder Johan Sandin.
-
Xbrane wins long-awaited FDA approval for eye drug biosimilar
After a long and winding road, Xbrane has now received FDA approval for Lucamzi, a biosimilar to the eye drug Lucentis.
-
New lung cancer combo shown to extend survival by eight months
A new drug combination extended survival by more than eight months in patients with extensive-stage small cell lung cancer, according to a late-stage clinical trial.
-
Enhertu wins EU approval in early breast cancer
AstraZeneca’s Enhertu is moving into earlier-stage breast cancer treatment after winning EU approval. In a phase III trial, the drug reduced the risk of invasive disease recurrence or death by 53 per cent compared with the current standard treatment.
-
Miris under pressure as sales fall – CEO steps down
Following a sharp decline in sales, Swedish medtech company Miris is planning a SEK 20 million rights issue. At the same time, long-serving CEO Camilla Myhre Sandberg is stepping down, while the company’s major shareholder is proposing changes to the board.
-
J&J hails early prostate cancer data as “the best we have ever seen”
A new prostate cancer pill achieved a tumour response in 75 per cent of patients whose tumours could be measured in a phase I study.
-
Roche scores phase III win with lung cancer drug
Roche’s investigational cancer drug divarasib reduced the risk of death by 44 per cent compared with existing treatments in a phase III trial involving patients with lung cancer.
-
Early gene therapy offers hope for some ALS patients
New treatments for ALS are raising hopes among researchers. “The earlier a patient receives targeted gene therapy, the greater their chances of living longer,” says Caroline Ingre, who heads ALS research at Karolinska Institutet in Sweden.
-
AstraZeneca’s ADC candidate beats expectations – new phase III data at ESMO
AstraZeneca’s experimental cancer treatment sone-ve delivered longer survival than analysts had expected in a phase III trial in advanced gastric cancer. The company also presented positive results for a combination with Imfinzi in bladder cancer at the ESMO congress in Madrid.
-
Vitrolife appoints Elin Frostehav as new CEO
Elin Frostehav is leaving Getinge to take up the role of CEO at Vitrolife.
-
Lilly’s obesity ads on the underground cleared by watchdog
Eli Lilly’s advertising campaign about obesity did not breach industry rules on advertising aimed at the general public, according to a ruling by the Swedish pharmaceutical industry’s Information Examination Board (IGN).
-
UK ends uncertainty over CE marking for medical devices
Medical device manufacturers will be spared duplicate certification processes to access the British market. The UK government has decided to recognise CE marking indefinitely, a move welcomed by industry.
-
”Cybersecurity Is Patient Safety”
Avivit Kotler, Chief Information Security and Data Protection Officer at Clalit Health Services in Israel will participate in the MVA Annual Summit 2026 November 2nd in Copenhagen. Kotler will share key insights regarding the cybersecurity threats facing Western healthcare systems. She will also discuss Israel’s experience in combating the threats its own healthcare system has recently faced.
BREAKING